Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
7/03/2016
1
The clinical spectrum of pulmonary aspergillosis
Pascal Van Bleyenbergh, Pneumologie UZ Leuven
Pentalfa 3 maart 2016
Aspergillus species• First described in 1729 * >250 species * ubiquitous
• Inhalation of conidia common * only minority lung disease
• Most common cause of mortality due to invasive mycosis
• Variety of clinical syndromes
Latge JP. Clin Microbiol Rev 1999; 12: 310-350
7/03/2016
2
Broad Spectrum of Pulmonary Aspergillosis
Kosmidis C, Denning DW. Thorax 2015; 70(3): 270-277
SAFS
Broad Spectrum of Pulmonary Aspergillosis
Hope WW et al. Med Mycol 2005; 43(Suppl 1): 207–38
7/03/2016
3
Chronic pulmonary aspergillosis (CPA)
Chronic pulmonary aspergillosis (CPA)
- 1842: ‘parasitic vegetable structures’ (Bennett J)- 1938: ‘mega-mycetoma intra-bronchiectasique’ (Deve F)- 1957: amphotericine B for treating chronic aspergillosis complicating TB
(Kelmenson VA)- 1981: ‘semi-invasive pulmonary aspergillosis’ (Gefter WB et al.)- 1982: ‘chronic necrotizing pulmonary aspergillosis’ (Binder RE et al.)
Gefter WB et al. Radiology 1981; 140: 313-321Binder RE et al. Medicine 1982; 61: 109-124
7/03/2016
4
Chronic Pulmonary Aspergillosis (CPA)
Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
5
Simple (single) aspergilloma• Fungal ball (= hyphae and extracellular matrix)
• Pre-existing cavity: lung, pleura, ectatic bronchus
• Characteristic imaging features (RX / CT)
• Serological or microbiological evidence implicating Aspergillus
• No progression over 3 months
• No or very few pulmonary/systemic symptoms
• Non-immunocompromised patient
Denning DW et al. Eur Resp J 2016; 47: 45-68
Simple (single) aspergilloma
Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
6
Aspergillus nodule• One or more nodules
• <3cm,only rarely >3cm (with necrotic centre)
• Usually no cavitation
• No tissue invasion
• Unusual presentation of CPA…
• Broad differential diagnosis (lung carcinoma, metastases, other fungal infection, ...)
Denning DW et al. Eur Resp J 2016; 47: 45-68
Aspergillus nodule
Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
7
Chronic cavitary pulmonary aspergillosis (CCPA)
• Multiple cavities +/- fungal ball
• Radiological progression over 3 months(new cavities, increasing infiltrates, increasing fibrosis)
• Significant pulmonary/systemic symptoms
• Serological or microbiological evidence implicating Aspergillus
• CFPA (chronic fibrosing pulmonary aspergillosis) is end result of CCPA with extensive fibrotic destruction of at least two lobes!
= most frequent presentation of CPA!
Denning DW et al. Clin Infect Dis 2003; 37(Suppl3): 265-280
Chronic cavitary pulmonary aspergillosis (CCPA)
Denning DW et al. Clin Infect Dis 2003; 37(Suppl3): 265-280
7/03/2016
8
Chronic cavitary pulmonary aspergillosis (CCPA)
Denning DW et al. Clin Infect Dis 2003; 37(Suppl3): 265-280
Subacute invasive pulmonary aspergillosis (SAIA)
• ‘chronic necrotizing’ or ‘semi-invasive’ pulmonary aspergillosis
• Clinically and radiologically similar to CCPA but more rapid in progression (<<3 months)
• Mildly immunocompromised patient / structural lung disease(diabetes, malnutrition, alcoholism, advanced age, prolonged corticosteroidtherapy, COPD, connective tissue disorder, radiation therapy, NTM disease, HIV,…)
• Serological or microbiological evidence implicating Aspergillus
• Signs of invasive disease possible (hyphae in lung tissue)
Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
9
Subacute invasive pulmonary aspergillosis (SAIA)
Denning DW et al. Eur Resp J 2016; 47: 45-68
Subacute invasive pulmonary aspergillosis (SAIA)
Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
10
Chronic pulmonary aspergillosis – diagnostic criteria
Denning DW et al. Eur Resp J 2016; 47: 45-68
Chronic pulmonary aspergillosis – diagnostic criteria
1.1 Characteristic CT appearance of a fungus ball in a pulmonary or pleural cavity, or dilated bronchus
Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
11
Chronic pulmonary aspergillosis – diagnostic criteria
1.1 Characteristic CT appearance of a fungus ball in a pulmonary or pleural cavity, or dilated bronchusOR1.2 Radiological features consistent with chronic pulmonary aspergillosis (cavities, pleural thickening, extensive fibrosis, nodules,…)
Denning DW et al. Eur Resp J 2016; 47: 45-68
Chronic pulmonary aspergillosis – diagnostic criteria
1.1 Characteristic CT appearance of a fungus ball in a pulmonary or pleural cavity, or dilated bronchusOR1.2 Radiological features consistent with chronic pulmonary aspergillosis (cavities, pleural thickening, extensive fibrosis, nodules,…)
AND2. Clinical or radiological evidence of at least 3 months disease (shorter duration possible for SAIA)
Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
12
Chronic pulmonary aspergillosis – diagnostic criteria
1.1 Characteristic CT appearance of a fungus ball in a pulmonary or pleural cavity, or dilated bronchusOR1.2 Radiological features consistent with chronic pulmonary aspergillosis (cavities, pleural thickening, extensive fibrosis, nodules,…)
AND2. Clinical or radiological evidence of at least 3 months disease (shorter duration possible for SAIA)
AND3. Histological or microbiological or immunological evidence of Aspergillusinfection (hyphae in biopsy or Asp. culture in cavity aspiration, strongly positive BAL GM, positive IgG/precipitins). Respiratory tract cultures or PCR positive for Aspergillus is supportive.
Denning DW et al. Eur Resp J 2016; 47: 45-68
Histological or microbiological or immunological evidence of Aspergillus infection
Biopsy or resection of lesions: definitive distinction between SAIA and CCPA
Presence of Aspergillus in respiratory secretions (stain, cultures, PCR)- supportive but not diagnostic- suboptimal sensitivity (56%-81%)- culture: media specific for fungi- PCR more sensitive than culture- persistance during antifungal therapy resistance!
Galactomannan- BAL >> serum- much higher sensitivity and specificity (85,7% & 77%)
Aspergillus antibodies (IgG, precipitins – no role of IgA & IgM)- key diagnostic feature in CPA- antibody titers no correlation with extent of severity of disease (…)
Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
13
Chronic pulmonary aspergillosis – diagnostic criteria1.1 Characteristic CT appearance of a fungus ball in a pulmonary or pleural cavity, or dilated bronchus1.2 Radiological features consistent with chronic pulmonary aspergillosis
2. Clinical or radiological evidence of at least 3 months disease
3. Histological or microbiological or immunological evidence of Aspergillus infection
AND
Exclusion of
- active bacterial infection, including mycobacterial infection
- actinomycosis
- histoplasmosis and (para)coccidioidomycosis in endemic areas
- malignancies, vasculitides, rheumatoid nodules,…
Denning DW et al. Eur Resp J 2016; 47: 45-68
Diagnosis of SAIA= diagnosis of IPA in the immunocompromised host (EORTC)
De Pauw B et al. Clin Infect Dis 2008; 46: 1813-1821
7/03/2016
14
Diagnosis of SAIA= diagnosis of IPA in the immunocompromised host (EORTC)
Bulpa P et al. Eur Resp J 2007; 30: 782-800
4) Positive BAL galactomannan test
Underlying conditions in pts with CPA
Smith NL et al. Eur Respir J 2011; 37: 865-872Godet C et al. Resp 2014; 88: 162-174
7/03/2016
15
CPA in patients with COPD
Guinea J et al. Clin Microbiol Infect 2010; 16: 870-877
2000-200714.618 COPD admissions
16,3 Asp.+/1000 admissions53 ‘probable’ PA➜ 3,6/1000 admissions➜ 22,1% if Asp.+
CPA in patients with NTM disease
• 11% of NTM patients (3,9% - 16,7%)
• CCPA >> CNPA (89% vs 11%)
• Cavitary NTM disease
• Prior use of corticosteroids
• Poorer prognosis
• Interactions with azoles!➪ CPA >> NTM treatment
Kunst H et al. Eur Resp J 2006; 28: 352-357Kazuaki T et al. Med Myc 2016; 54: 120-127
7/03/2016
16
Therapy for CPA• Cohort studies and case reports; only 2 larger prospective studies
• Aspergilloma: surgery is first choice!
• Oral azole therapy for CCPA is standard of care!➜ itraconazole, voriconazole, posaconazole
Agarwal R et al. Mycoses 2013; 56: 559-570Denning DW et al. Eur Resp J 2016; 47: 45-68
Therapy for CPA• Cohort studies and case reports; only 2 larger prospective studies
• Aspergilloma: surgery is first choice!
• Oral azole therapy for CCPA is standard of care!➜ itraconazole, voriconazole, posaconazole
• SAIA: treat as invasive pulmonary aspergillosis! (IDSA/ATS guidelines)
• Response to antifungal treatment is slow…
• Duration: 4-6 months 9 months12 months
• Quid indefinite long-term suppressive therapy?
Agarwal R et al. Mycoses 2013; 56: 559-570Denning DW et al. Eur Resp J 2016; 47: 45-68
7/03/2016
17
CPA: treatment needs to be “long term”
Denning DW et al. Eur Resp J 2016; 47: 45-68
CPA: treatment needs to be “long term”
Cadranel J et al. Eur J Clin Microbiol Infect Dis 2012; 31: 3231-3239 --- Al-shair K et al. Clin Infect Dis 2013; 57: 828-835 Agarwal R et al. Mycosis 2013; 56: 559-570
7/03/2016
18
CPA:global treatment strategy
Godet C et al. Resp 2014; 88: 162-174Ohara S et al. Resp Invest 2016; 54: 92-97
• Attention for co-morbidities
smoking, alcohol intake
malnutrition
corticosteroids
• Pulmonary rehabilitation